A late-stage clinical trial was conducted by Biogen and Eisai and the new Alzheimer’s drug they are developing for Alzheimer’s disease slowed the rate of cognitive decline. New Alzheimer’s Drug …
Research Study Shows New Alzheimer’s Drug Slows Cognitive Decline Read More »
Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly …
First Florida Patient to Receive Biogen Aducanumab Infusion Read More »
In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause …
Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the …
Leading Florida Neurologists Available to Speak about Biogen Aducanumab Treatment Alzheimer’s patients and their families, as well as the medical community, are celebrating today’s decision by the FDA to approve …
The holidays can be a stressful time, especially for families of a loved one diagnosed with Alzheimer’s disease. When a family member has dementia or Alzheimer’s disease, the family dynamic …
